tradingkey.logo
tradingkey.logo
Search

Maravai LifeSciences Holdings Inc

MRVI
Add to Watchlist
4.290USD
-0.080-1.83%
Close 05/14, 16:00ETQuotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM

Maravai LifeSciences Holdings Inc

4.290
-0.080-1.83%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-1.83%

5 Days

+8.88%

1 Month

+30.79%

6 Months

+17.86%

Year to Date

+32.00%

1 Year

+116.67%

Key Insights

Maravai LifeSciences Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.70.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Maravai LifeSciences Holdings Inc's Score

Industry at a Glance

Industry Ranking
32 / 383
Overall Ranking
122 / 4487
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Maravai LifeSciences Holdings Inc Highlights

StrengthsRisks
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Undervalued
The company’s latest PE is -6.05, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 140.69M shares, decreasing 17.15% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 3.06K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.29.

Analyst Rating

Based on 10 analysts
Buy
Current Rating
5.700
Target Price
+20.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Maravai LifeSciences Holdings Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Maravai LifeSciences Holdings Inc Info

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Ticker SymbolMRVI
CompanyMaravai LifeSciences Holdings Inc
CEOBrust (Bernd)
Websitehttps://www.maravai.com/
KeyAI